Yun Young Lee

Yun Young Lee

Auto-generated profile, based on publicly available information

Yun Young Lee

Gencurix, Inc

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Journal of Industrial and Engineering Chemistry
Verified
Journal Article
Closed access
SKSena Kim
Sena Kim
CPChun Gwon Park
Chun Gwon Park
CMChang Hee Min
Chang Hee Min
SLSeung Ho Lee
Seung Ho Lee
YLYun Young Lee
Yun Young Lee
YCYoung Bin Choy
Young Bin Choy

1 July 2017 in Clinical Therapeutics
Verified
Journal Article
Closed access
MOMi Jin Oh
Mi Jin Oh
HHHyun Hwan Hwang
Hyun Hwan Hwang
HKHyun Gyu Kim
Hyun Gyu Kim
GLGeun Hyeog Lee
Geun Hyeog Lee
YCYun-Seok Cho
Yun-Seok Cho
HYHan Young Yu
Han Young Yu


20 April 2026 in Epigenetics
Verified
Journal Article
Open access
SPSun Jae Park
Sun Jae Park
YLYun Young Lee
Yun Young Lee
YCYong-Kyu Chung
Yong-Kyu Chung
BJBo-Hyun Jung
Bo-Hyun Jung
JAJoon An
Joon An
HWHee-Jung Wang
Hee-Jung Wang
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, yet current surveillance with alpha-fetoprotein (AFP) and ultrasound (US) lacks sufficient accuracy, particularly for early-stage disease. This study aimed to develop and clinically validate a blood-based digital PCR (dPCR) assay targeting novel methylation biomarkers for HCC detection. Genome-wide methylation profiles from HCC, normal, and other cancer types were analysed to identify candidates, which were then screened and verified in cancer cell lines, primary tumour tissues, and plasma specimens. A total of 186 plasma samples were evaluated, including 66 healthy controls, 60 patients with chronic liver disease (CLD) without HCC, and 60 patients with HCC. FAR1 methylation emerged as an HCC-specific biomarker, showing significantly higher levels in liver cancer cell lines and HCC tumour tissues compared with controls. A dPCR assay targeting FAR1 achieved 70.0% sensitivity (42/60; 95% CI, 56.8%–81.2%) and 96.8% specificity (122/126; 95% CI, 92.1–99.1%), with an area under the curve (AUC) of 0.90 (95% CI, 0.85–0.96). Combining FAR1 with AFP improved sensitivity to 88.3% (53/60; 95% CI, 77.4%–95.2%) while maintaining 96.8% specificity. Notably, early-stage HCC (Barcelona Clinic Liver Cancer [BCLC] stage 0–A) was detected with 85.4% sensitivity (35/41; 95% CI, 77.4%–94.4%). This blood-based dPCR assay demonstrated high diagnostic performance, underscoring its potential as a noninvasive tool to enhance early detection and clinical management of HCC in high-risk populations.

3 February 2026 in Annals of Transplantation
Verified
Journal Article
Open access
BNByeong-Gon Na
Byeong-Gon Na
SHShin Hwang
Shin Hwang
JHJinil Han
Jinil Han
DJDong-Hwan Jung
Dong-Hwan Jung
GSGi-Won Song
Gi-Won Song
YKYun-Kyu Kim
Yun-Kyu Kim
BACKGROUND Recent research has highlighted DNA methylation as a promising diagnostic biomarker for hepatocellular carcinoma (HCC). Fatty Acyl-CoA Reductase 1 (FAR1) exhibits a high propensity for methylation in HCC. This study aimed to evaluate diagnostic and prognostic potential of FAR1 methylation in liver transplantation (LT) recipients with HCC. MATERIAL AND METHODS This analysis used droplet digital polymerase chain reaction to quantify FAR1 methylation levels in stored pretransplant blood samples. The study cohort (n=48) comprised 25 liver cirrhosis patients with HCC, 13 with cirrhosis but no HCC, and 10 healthy donors. RESULTS Median and mean methylation levels of FAR1 in these groups were 4 copies, zero copies, and zero copies, and 31.6±74.5, 1.5±3.5, and 0.1±0.4 copies, respectively (p1 copy with AFP >7.5 ng/mL or PIVKA-II >40 mAU/mL increased the sensitivity to 91.3%, with specificity of 72.7% and overall accuracy of 82.2%. There was no significant correlation between FAR1 methylation levels and tumor recurrence or overall survival when using a cut-off of 1 copy. CONCLUSIONS These findings suggest that FAR1 methylation is a valuable biomarker for diagnosing HCC in patients with advanced liver disease awaiting transplantation. Further large-scale investigations are necessary to validate clinical efficacy.